1 option
Clinical review report : (ViiV healthcare). Dolutegravir/Rilpivirine (Juluca) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- HIV infections.
- Antiretroviral agents.
- Outcome assessment (Medical care).
- Physical Description:
- 1 online resource (26 pages)
- Edition:
- Final clinical review report (with redactions).
- Place of Publication:
- Ottawa (ON) : CADTH, 2018.
- Summary:
- The objective of this systematic review was to evaluate the beneficial and harmful effects of Juluca, a fixed-dose combination of dolutegravir (an INSTI) plus rilpivirine (an NNRTI), as a complete regimen to replace the current antiretroviral regimen for the treatment of HIV-1 infection in adults who are virologically stable and suppressed (HIV-1 RNA < 50 copies/mL).
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.